Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hopkins

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Patient Education and Counseling|September 6, 2023
Which diabetes specific patient reported outcomes should be measured in routine care? A systematic review to inform a core outcome set for adults with Type 1 and 2 diabetes mellitus: The European Health Outcomes Observatory (H2O) programmeKathryn Hamilton, Rita Forde, Mette Due-Christensen, et al.
Schizophrenia Research|July 31, 2017
Hyperprolactinaemia in first episode psychosis - A longitudinal assessmentJohn Lally, Olesya Ajnakina, Brendon Stubbs, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 2, 2022
Multimodal testing reveals subclinical neurovascular dysfunction in prediabetes, challenging the diagnostic threshold of diabetesVaro Kirthi, Kate I Reed, Komeil Alattar, et al.
Gut|July 24, 2019
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre studyAnnieke C G van Baar, Frits Holleman, Laurent Crenier, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 27, 2019
Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyFiona Gaughran, Daniel Stahl, Dominic Stringer, et al.
The Lancet. Diabetes & Endocrinology|April 27, 2020
Practical recommendations for the management of diabetes in patients with COVID-19Stefan R Bornstein, Francesco Rubino, Kamlesh Khunti, et al.
BMC Psychiatry|December 24, 2017
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotionMargaret Heslin, Anita Patel, Daniel Stahl, et al.
Plos One|November 9, 2020
Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infectionLiam Townsend, Adam H Dyer, Karen Jones, et al.
Cell Death & Disease|June 4, 2026
NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in miceDaniel Egbase, Sophie R Sayers, Naila Haq, et al.
Diabetes Research and Clinical Practice|January 15, 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)Annieke C G van Baar, Jacques Devière, David Hopkins, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Patient Education and Counseling|September 6, 2023
Which diabetes specific patient reported outcomes should be measured in routine care? A systematic review to inform a core outcome set for adults with Type 1 and 2 diabetes mellitus: The European Health Outcomes Observatory (H2O) programmeKathryn Hamilton, Rita Forde, Mette Due-Christensen, et al.
Schizophrenia Research|July 31, 2017
Hyperprolactinaemia in first episode psychosis - A longitudinal assessmentJohn Lally, Olesya Ajnakina, Brendon Stubbs, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|September 2, 2022
Multimodal testing reveals subclinical neurovascular dysfunction in prediabetes, challenging the diagnostic threshold of diabetesVaro Kirthi, Kate I Reed, Komeil Alattar, et al.
Gut|July 24, 2019
Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre studyAnnieke C G van Baar, Frits Holleman, Laurent Crenier, et al.
The British Journal of Psychiatry : the Journal of Mental Science|July 27, 2019
Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort studyFiona Gaughran, Daniel Stahl, Dominic Stringer, et al.
The Lancet. Diabetes & Endocrinology|April 27, 2020
Practical recommendations for the management of diabetes in patients with COVID-19Stefan R Bornstein, Francesco Rubino, Kamlesh Khunti, et al.
BMC Psychiatry|December 24, 2017
Randomised controlled trial to improve health and reduce substance use in established psychosis (IMPaCT): cost-effectiveness of integrated psychosocial health promotionMargaret Heslin, Anita Patel, Daniel Stahl, et al.
Plos One|November 9, 2020
Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infectionLiam Townsend, Adam H Dyer, Karen Jones, et al.
Cell Death & Disease|June 4, 2026
NAMPT activity plays a key role in driving autoimmune processes that mediate beta-cell death and type 1 diabetes development in miceDaniel Egbase, Sophie R Sayers, Naila Haq, et al.
Diabetes Research and Clinical Practice|January 15, 2022
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)Annieke C G van Baar, Jacques Devière, David Hopkins, et al.
Pageof 9